Mein Warenkorb

DLL4

DLL4 Molekülinformation

Englischer NameDelta-like protein 4Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-AliasDelta-Like Protein 4,Notch Ligand Delta-2,DLL4,Delta4,Delta-Like 4 (Drosophila),Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Notch Ligand DLL4,Delta Like Canonical Notch Ligand 4,Delta 4,Delta Ligand 4,Delta-Like 4 Protein,Drosophila Delta Homolog 4,Delta-Like 4 Homolog
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameDelta-like protein 4
Target-AliasDelta-Like Protein 4,Notch Ligand Delta-2,DLL4,Delta4,Delta-Like 4 (Drosophila),Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Notch Ligand DLL4,Delta Like Canonical Notch Ligand 4,Delta 4,Delta Ligand 4,Delta-Like 4 Protein,Drosophila Delta Homolog 4,Delta-Like 4 Homolog
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

DLL4 Molekülhintergrund

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

DLL4 Molekülalias

DLL4,Delta4

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TovecimigES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001Phase 3 ClinicalAbl Bio IncAmpullary Carcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Rectal Neoplasms; Solid tumours
Details
NavicixizumabOMP-305B83Phase 3 ClinicalOncomed Pharmaceuticals IncColorectal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
DilpacimabABT-165; DVD-Ig ABT-165Phase 1 ClinicalAbbvie IncNeoplasms; Solid tumours
Details

Produktrezensionen

  • A***r2025-11-15
    0Menschen mögen
    I have been using ACRO Biosystems products since 2021, especially DLL4 Fc proteins (DL4-H5259), refer to our published article: https://pubmed.ncbi.nlm.nih.gov/37795096/, where we have used Acro-products and obtained excellent results. I am very satisfied with the consistent quality and reliability of ACRO’s products. Thanks, Ankit Tanwar Staff Scientist AECOM, NY
  • Z***a2022-07-06
    1Menschen mögen
    This product was extremely useful for our T cell work. The vial it came in was easy to use (sometimes you'd be surprised how obtuse the packaging of a compound can be by certain companies) and has not lead to any issues with our research in many months. The only obstacle we have ever faced with adherent cells was as a result of our flat bottom plates being too old (and thus the coating wore off). So this product was more stable and consistent than the plates we put them on!
  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns